The results of the clinical study demonstrated that using the biomarkers signature (CA-62, CEA and CYFRA 21-1) allows increasing the Specificity of CT diagnostics for patients with suspicious changes on the tomogram, improving the interpretation of visualized localized focus, and improving the accuracy of differential diagnosis at detecting early stages of LC up to 94%. The gene discussed is CEACAM5; the disease is laryngotracheoesophageal cleft.